Vincent Rajkumar: A Historic Day for High Risk Smoldering Myeloma
Vincent Rajkumar, Editor‑in‑Chief, Blood Cancer Journal, shared a post on X:
“A historic day for myeloma!! After 5 decades of research. European Commission/EMA approves Daratumumab as the first ever approved treatment for high risk smoldering myeloma based on the results of the AQUILA trial. AQUILA trial results.
In the AQUILA trial, daratumumab:
-Delayed progression to active myeloma
-Delayed time to needing full myeloma therapy
-Better overall survival
-Preserved quality of life.
The latest NCCN guidelines has also added daratumumab as Category 1 recommendation for high risk smoldering myeloma.”
Title: Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Authors: Meletios A. Dimopoulos, Peter M.Voorhees, Fredrik Schjesvold, Yael C. Cohen, Vania Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross I. Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark-David Levin, Meral Beksac, Keith Stockerl-Goldstein, Albert Oriol, Gabor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Spicka, Anne K.Mylin, Sara Bringhen, Katarina Uttervall, Bartosz Pula, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, Maria-VictoriaMateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G. Katz, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, and S. Vincent Rajkumar for the AQUILA Investigators.
Read More About Results of AQUILA Trial on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023